cancerfocused biopharmaceutical company olema pharmaceuticals inc said falsified information about a planned presentation circulated on social media the company said a falsified poster image about the phase 1 doseescalation portion of an op1250 phase 12 clinical trial wasnt released or authorized by olema olema was below its 2147 opening price for most of the day but spiked as high as 2570 during the afternoon shares were briefly paused due to volatility the stock was at 2189 up 5 for the day prior to being halted for news pending shares were recently at 2155 after hours olema is scheduled for two op1250 poster presentations at the san antonio breast cancer symposium being held dec 710 olema is also scheduled to participate in an evercore isi conference tuesday